Elpamotide
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 673478-49-4
- Fòrmula: C47H76N16O13
- Peso molecular:1073.21
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas VEGFR
More
Actividad biológica
Descripciòn
IC50 & Target
|
VEGFR2 |
In Vitro
Elpamotide shows potent and specific cytotoxicity in cytotoxic T lymphocytes (CTLs) (4-hour 51Cr-release assay) [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 673478-49-4
-
Peso molecular 1073.21
-
Fòrmula C47H76N16O13
-
Sequence Shortening
RFVPDGNRI
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Yamaue H, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci. 2015 Jul;106(7):883-90. [Content Brief]
[2]. Wada S, et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)